For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
Increase [drug] to 160 mg daily in patients receiving a strong CYP3A4 inducer.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
With regard to EGFR tumor testing in this trial, 63% of patients treated with [drug] were exon 19 deletion and 37% were exon 21 L858R; 5 patients (<1%) had a concomitant de novo T790M mutation.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
FLAURA Trial
Study 4
LUX-Lung 3 Trial
LUX-Lung 6 Trial
ARCHER 1050 Trial
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
The overall response rate in squamous cell carcinoma for the 335 patients treated with [drug] was 3% as compared to 2% for patients treated with erlotinib.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
[Drug] has shown OS data in the Del19 subgroup in 2 studies vs platinum doublet.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
Initially approved in 2013. FDA broadened indication in first-line treatment of metastatic NSCLC in January 2018.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
This was a randomized, double-blind, placebo-controlled trial in 731 patients with locally advanced or metastatic NSCLC after failure of at least one chemotherapy.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
FLAURA Trial
Study 4
LUX-Lung 3 Trial
LUX-Lung 6 Trial
ARCHER 1050 Trial
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
A global, randomized, open-label, Phase 3 study comparing first-line drug with cisplatin plus pemetrexed chemotherapy with advanced lung adenocarcinoma and proven EGFR mutations.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
FLAURA Trial
Study 4
LUX-Lung 3 Trial
LUX-Lung 6 Trial
ARCHER 1050 Trial
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
At the time of primary analysis of PFS, median overall survival was 22.1 months for this drug versus 22.2 months for gemcitabine and cisplatin.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
FLAURA Trial
Study 4
LUX-Lung 3 Trial
LUX-Lung 6 Trial
ARCHER 1050 Trial
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
[Drug] solubility is pH dependent. Drugs that alter the pH of the upper GI tract may alter the solubility of [drug] and hence its absorption.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
May cause decreased tear production, abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis and can lead to corneal perforation.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
H2 receptor antagonists have been shown to reduce absorption of [drug].
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
Food increased the bioavailability of this drug to approximately 100%.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
Evaluated in the first global, randomized, Phase 3 trial of 2 EGFR inhibitors head-to-head for first-line treatment of EGFR-activating, mutation-positive NSCLC patients.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
This drug was associated with a higher incidence of diarrhea and mucositis in two studies of patients with NSCLC compared with erlotinib.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
TAGRISSO® (osimertinib)
GILOTRIF® (afatinib)
TARCEVA® (erlotinib)
BRAND TBD (dacomitinib)
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
Within the subgroup analysis of progression-free survival in the ITT population in this clinical trial, there was no difference in effect of the two drugs between Asian and non-Asian subjects.
50
2
40
3
30
4
20
5
10
NEXT CLUE
SUBMIT
CONTINUE TO NEXT ROUND
ANSWER POOL:
FLAURA Trial
Study 4
LUX-Lung 3 Trial
LUX-Lung 6 Trial
ARCHER 1050 Trial
For internal use only. This document is not to be shared or distributed outside of AstraZeneca.
Round #
TIME:
YOUR SCORE:
0
CLUE
POINTS
1
In this study, 5% of patients in the test group achieved a complete response vs 2% in the comparator group.
